Aesthetics Biomedical® Inc. Announces Additional Positive Results Using Its Patented Topical Skincare Product SoME® Skincare In Combination With Platelet Rich Plasma
The new patent provides broader protections for the promotion of this novel technology that stands alone among the competition
PHOENIX, Feb. 24, 2021 /PRNewswire-PRWeb/ -- Aesthetics Biomedical® Inc. (ABM), a regenerative aesthetics medical device and topical skincare company announces additional scientific findings for its patented skincare product, SoME® Skincare that confirm earlier findings. (J Drugs & Dermatology Vol 19, Issue 12, Dec 2020). SoME® Skincare is the first in its class, utilizing personalized autologous platelet rich plasma (PRP) in a topical skincare product for ninety (90) days of home use. An earlier controlled, double blinded, eight-week study demonstrated, tolerability and efficacy of the topical product for facial rejuvenation. (J Cosmetic Dermatol Vol 18, Issue 5, 2019). The earlier data reported that the patented cosmetic base when combined with autologous PRP demonstrated increased efficacy with continued twice/day use. Dermatologist evaluation identified visible clinical improvement for signs of facial aging at four (4) weeks, with enhanced performance observed at eight (8) weeks (e.g. luminosity, radiance, smoothness, reduction in redness and skin lightening) vs. the control base alone. Biopsies revealed enhanced collagen and elastin expression including up-regulation of the type 1 collagen gene observed with the SoME® Skincare base + PRP vs. the SoME® Skincare base alone.
The recent findings demonstrated that the clinical efficacy was more robust at one hundred and twenty (120) days of daily use for all clinical end points, including identifiable reduction in fine lines and wrinkles. Comparable clinical, histological and biochemical results were observed with either 60mls or 20mls collection of whole blood. This fact improves the overall utilization of the product in the physician's office.
The patented cosmetic base is formulated to preserve viable platelet function for ninety (90) days of home use. As a point of care product, the patient goes to their physician office, blood is drawn and centrifuged to obtain PRP. 3mL of PRP is then added to each of three 1oz cosmetic base bottles providing for ninety (90) days, twice/day home use. The patient receives a mini refrigerator to store the product. The removal of the product from the refrigerator and applied to the skin provides a temperature change which activates and degranulates the platelets with ensuing release of growth factors and other biomolecules into the skin. Both light and scanning electron microscopy (SEM) demonstrated platelet activation and degranulation with product treatment. Enzyme linked assays demonstrated that the SoME® Skincare product could prevent release of key growth factors, for upwards to ninety (90) days. The product is well tolerated by all skin types; the preservative system is effective against bacteria, yeast and viruses, including HIV. Other in-office aesthetic treatments can be used concurrently with SoME® Skincare.
The new patent provides broader protections for the promotion of this novel technology that stands alone among the competition.
"We remain very excited with the most recent findings that supports the performance of our SoME® Skincare product and its growing adoption into aesthetic physician practices. We strongly believe a solid science foundation, coupled with product performance provides our physician community and patients with an exceptional topical product to address anti-aging and other aesthetic conditions. Further, we are moving forward in 2021 on multiple international registrations to bring SoME® Skincare into the global marketplace," says MaryAnn Guerra, ABM's President/CEO.
"Conducting double-blinded, split face, controlled clinical studies is a compelling way to evaluate the performance of a new topical skincare product. Dermatologist evaluation, histology, biochemistry and molecular approaches coupled with patient feedback, provides, multiple data sets to understand the mechanism of action, and provide improvements with follow-on products, says Lawrence Rheins PhD, ABM's Chief Scientific Officer. Consumers want personalized, natural products that perform, physicians, want to better understand the products performance. SoME® Skincare product provides both," says Rheins.
ABOUT AESTHETICS BIOMEDICAL®
Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. Visit http://www.AestheticsBiomedical.com or http://www.SoMESkincare.com
Media Contact
Sheldon Larson, Aesthetics Biomedical Chief Marketing Officer, +1 602-682-6423, [email protected]
SOURCE Aesthetics Biomedical
Share this article